(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
08 June 2023 (08.06.2023)

WIPO | PCT

(10) International Publication Number
WO 2023/101607 A3

(51) International Patent Classification:
C07K 14/47 (2006.01) *A61P 9/00* (2006.01)
A61K 38/16 (2006.01) *A61P 21/00* (2006.01)
A61P 3/06 (2006.01)

(21) International Application Number:
PCT/SG2022/050871

(22) International Filing Date:
30 November 2022 (30.11.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10202113391P 01 December 2021 (01.12.2021) SG

(71) Applicants: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). **NUEVOCOR PTE. LTD.** [SG/SG]; 1 Biopolis Drive, #05 - 01 Amnios, Singapore 138622 (SG).

(72) Inventors: **LEE, Yin Loon**; c/o Institute of Medical Biology, 8A, Immunos, Biomedical Grove, #06-06, Singapore 138648 (SG). **BURKE, Brian**; c/o Institute of Medical Biology, 8A, Immunos, Biomedical Grove, #06-06, Singapore 138648 (SG). **WERNER, Hendrikje**; c/o Nuevocor Pte. Ltd., 1 Biopolis Drive, #05 - 01 Amnios, Singapore 138622 (SG). **TAN, Yann Chong**; c/o Nuevocor Pte. Ltd., 1 Biopolis Drive, #05 - 01 Amnios, Singapore 138622 (SG). **RUSSELL, David W.**; c/o Nuevocor Pte. Ltd., 1 Biopolis Drive, #05 - 01 Amnios, Singapore 138622 (SG).

(74) Agent: **DONALDSON & BURKINSHAW LLP**; 24 Raffles Place, #15-00 Clifford Centre, Singapore 048621 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI,

(54) Title: LINC COMPLEX INHIBITING POLYPEPTIDES




Figure 2

(57) Abstract: The invention relates to nucleic acids encoding dominant negative polypeptides comprising the a3 helix of CC2 region and the SUN domain of a SUN domain-containing protein that inhibit the LING complex. The specific embodiment relates to polypeptides of varying lengths derived from amino acids 404-812 of SUN1 with a KDEL signal sequence. It also relates to methods of identifying a LING complex inhibitor and the use of said polypeptides for treating and preventing laminopathies, and diseases characterised by hyperlipidaemia.

[Continued on next page]

WO 2023/101607 A3

SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
10 August 2023 (10.08.2023)